A National Survey of Provisions in Clinical-Trial Agreements Between Medical Schools and Industry Sponsors
Schulman, Kevin A.
Seils, Damon M.
Timbie, Justin W.
Dame, Lauren A.
Weinfurt, Kevin P.
Mark, Daniel B.
Califf, Robert M.
New England Journal of Medicine 2002 October 24; 347(17): 1335-1341
BACKGROUND: Concerned about threats to the integrity of clinical trials in a research environment increasingly controlled by private interests, the International Committee of Medical Journal Editors (ICMJE) has issued revised guidelines for investigators' participation in the study design, access to data, and control over publication. It is unclear whether research conducted at academic institutions adheres to these new standards. METHODS: From November 2001 through January 2002, we interviewed officials at U.S. medical schools about provisions in their institutions' agreements with industry sponsors of multicenter clinical trials. A subgroup of the respondents were also asked about coordinating-center agreements for such trials. RESULTS: Of the 122 medical schools that are members of the Association of American Medical Colleges, 108 participated in the survey. The median number of site-level agreements executed per institution in the previous year was 103 (interquartile range, 50 to 210). Scores for compliance with a wide range of provisions--from ensuring that authors of reports on multicenter trials have access to all trial data (1 percent [interquartile range, 0 to 21]) to addressing the plan for data collection and monitoring (10 percent [interquartile range, 1 to 50])--demonstrated limited adherence to the standards embodied in the new ICMJE guidelines. Scores for coordinating-center agreements were somewhat higher for most survey items. CONCLUSIONS: Academic institutions routinely engage in industry-sponsored research that fails to adhere to ICMJE guidelines regarding trial design, access to data, and publication rights. Our findings suggest that a reevaluation of the process of contracting for clinical research is urgently needed. Copyright 2002 Massachusetts Medical Society
Clinical Trials; Data Collection; Environment; Guidelines; Industry; Investigators; Medical Schools; Methods; Research; Rights; Schools; Standards; Survey; Social Control of Science and Technology; Human Experimentation Policy Guidelines / Institutional Review Boards; Social Control of Human Experimentation;
Showing items related by title, author, creator and subject.
Meyer, Roger E.; Korn, David; Schulman, Kevin A.; Seils, Damon M.; Califf, Robert M. (2003-01-30)
Consistency of Financial Interest Disclosures in the Biomedical Literature: The Case of Coronary Stents Weinfurt, Kevin P.; Seils, Damon M.; Tzeng, Janice P.; Lin, Li; Schulman, Kevin A.; Califf, Robert M. (2008-05)
Expectations of Benefit in Early-Phase Clinical Trials: Implications for Assessing the Adequacy of Informed Consent Weinfurt, Kevin P.; Seils, Damon M.; Tzeng, Janice P.; Compton, Kate L.; Sulmasy, Daniel P.; Astrow, Alan B.; Solarino, Nicholas A.; Schulman, Kevin A.; Meropol, Neal J. (2008-07)